Resverlogix (RVX; Calgary, Alberta), developer of compounds for use with medical devices, has found a partner for its early-stage pharma technology, ReVas, for a large cardiovascular application. The company will work with Medtronic (Minneapolis), to create a drug-eluting (DES) stent, as the med-tech titan seeks to be the third to enter the DES derby.